

Bladder Cancer - Pipeline Review, H1 2020

<https://marketpublishers.com/r/B21AD9F58C2EN.html>

Date: June 2020

Pages: 1855

Price: US\$ 2,500.00 (Single User License)

ID: B21AD9F58C2EN

Abstracts

Bladder Cancer - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H1 2020, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-

Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 14, 76, 93, 1, 4, 93, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 8, 4, 1, 12 and 3 molecules, respectively. Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Bladder Cancer - Overview

Bladder Cancer - Therapeutics Development

Bladder Cancer - Therapeutics Assessment

Bladder Cancer - Companies Involved in Therapeutics Development

Bladder Cancer - Drug Profiles

Bladder Cancer - Dormant Projects

Bladder Cancer - Discontinued Products

Bladder Cancer - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Bladder Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1),
H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Route of Administration, H1 2020 (Contd..1), H1
2020
Number of Products by Stage and Molecule Type, H1 2020
Bladder Cancer - Pipeline by 4D Pharma Plc, H1 2020
Bladder Cancer - Pipeline by 4SC AG, H1 2020
Bladder Cancer - Pipeline by Aadi Bioscience Inc, H1 2020
Bladder Cancer - Pipeline by AbbVie Inc, H1 2020
Bladder Cancer - Pipeline by Abivax SA, H1 2020
Bladder Cancer - Pipeline by Actuate Therapeutics Inc, H1 2020
Bladder Cancer - Pipeline by ADC Therapeutics SA, H1 2020
Bladder Cancer - Pipeline by Aduro BioTech Inc, H1 2020
Bladder Cancer - Pipeline by Advaxis Inc, H1 2020
Bladder Cancer - Pipeline by Agenus Inc, H1 2020
Bladder Cancer - Dormant Projects, H1 2020
Bladder Cancer - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bladder Cancer, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4D Pharma Plc
4SC AG
Aadi Bioscience Inc
AbbVie Inc
Abivax SA
Actuate Therapeutics Inc
ADC Therapeutics SA
Aduro BioTech Inc
Advaxis Inc
Agenus Inc
AIM ImmunoTech Inc
Alligator Bioscience AB
Alphamab Oncology
Altor Bioscience LLC
Amrita Therapeutics
Andes Biotechnologies
Angex Pharmaceutical Inc
Apexian Pharmaceuticals Inc
APIM Therapeutics AS
Apollomics Inc
Aprea Therapeutics AB

Aravive Inc
Archivel Farma SL
Arcus Biosciences Inc
Arisaph Pharmaceuticals Inc
Asieris Pharmaceuticals Co Ltd
AstraZeneca Plc
Aura Biosciences Inc
Aurigene Discovery Technologies Ltd
Aurora Oncology Inc
Bavarian Nordic A/S
Bayer AG
BeiGene Ltd
Beijing Neoantigen Biotechnology Co Ltd
BerGenBio ASA
Betta Pharmaceuticals Co Ltd
BeyondSpring Inc
Bio-Thera Solutions Ltd
BioAtla LLC
Biocad
Biohaven Pharmaceutical Holding Company Ltd
BioMed Valley Discoveries Inc
Biomics Biotechnologies Co Ltd
BioNTech SE
Biosion Inc
Black Diamond Therapeutics Inc
Bliss Biopharmaceutical (Hangzhou) Co Ltd
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Cantargia AB
CDR-Life Inc
CellCentric Ltd
Celldex Therapeutics Inc
Celon Pharma SA
Celprogen Inc
Celsion Corp
Celyad Oncology
CG Oncology Inc
Checkmate Pharmaceuticals Inc
CheckPoint Immunology Inc

CicloMed LLC
Cleveland BioLabs Inc
CMG Pharmaceutical Co Ltd
Constellation Pharmaceuticals Inc
Convalife
Corvus Pharmaceuticals Inc
CStone Pharmaceuticals Co Ltd
Cytodyn Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
DeMar Pharmaceuticals Inc
Ectin Research AB
Eddingpharm Inc
Eisai Co Ltd
Emtara Biosciences
ENB Therapeutics LLC
enGene Inc
EnGeneIC Ltd
EpiVax Oncology Inc
Esperance Pharmaceuticals Inc
Evelo Biosciences Inc
Exelixis Inc
Exicure Inc
EXUMA Biotech Inc
F. Hoffmann-La Roche Ltd
Fidia farmaceutici SpA
FKD Therapies Oy
For-Robin Inc
Fusion Pharmaceuticals Inc
Gene Signal International SA
Genentech Inc
Genexine Inc
Genmab AS
Genome & Co
Gilead Sciences Inc
GlaxoSmithKline Plc
GLG Pharma SA
GlycoNex Inc
H3 Biomedicine Inc

Hamlet Pharma AB
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
HengRui YuanZheng Bio-Technology Co Ltd
Hope Biosciences Inc
Horizon Therapeutics Plc
Huabo Biopharm Co Ltd
I-Mab Biopharma Co Ltd
ImCheck Therapeutics SAS
ImmunityBio Inc
Immunocore Ltd
Immunomic Therapeutics Inc
ImmunSYS Inc
Immupharma Plc
Imugene Ltd
IMV Inc
Incanthera Ltd
Incyte Corp
Innovative Cellular Therapeutics Co Ltd
Innovent Biologics Inc
Invectys SA
Iovance Biotherapeutics Inc
Jacobio Pharmaceuticals Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
KLUS Pharma Inc
Komipharm International Co Ltd
Kyowa Kirin Co Ltd
Lipac Oncology LLC
LipoMedix Pharmaceutical Inc
LipoSeuticals Inc
Loxo Oncology Inc
Luye Pharma Group Ltd
Lycera Corp
Machavert Pharmaceuticals LLC
MacroGenics Inc
Manhattan Biosolutions LLC
MaxiVAX SA
Mediolanum farmaceutici SpA

Medivir AB
MedPacto Inc
MELEMA Pharma GmbH
Merck & Co Inc
Merck KGaA
Midissia Therapeutics Inc
Millennium Pharmaceuticals Inc
Modra Pharmaceuticals BV
Molecular Partners AG
Molecular Templates Inc
Moleculin Biotech LLC
Morvus Technology Ltd
MTG Biotherapeutics Inc
Mustang Bio Inc
Nanjing Transthera Biosciences Co Ltd
NanoCarrier Co Ltd
Nanology LLC
NantKwest Inc
Nektar Therapeutics
NeoTX Therapeutics Ltd
NGM Biopharmaceuticals Inc
Northwest Biotherapeutics Inc
Novartis AG
Ocellaris Pharma Inc
Ona Therapeutics SL
OncoSTING LLC
OncoTherapy Science Inc
Oncovir Inc
Ono Pharmaceutical Co Ltd
Optimum Therapeutics LLC
Oxford BioTherapeutics Ltd
Peptron Inc
Pfizer Inc
Pharma Mar SA
Pieris Pharmaceuticals Inc
Plus Therapeutics Inc
Prokarium Ltd
Provecs Medical GmbH
PsiOxus Therapeutics Ltd

Puma Biotechnology Inc
Qu Biologics Inc
Quadriga BioSciences Inc
Ractigen Therapeutics Inc
Rainier Therapeutics Inc
RemeGen Ltd
Replimune Ltd
Rexahn Pharmaceuticals Inc
Sanofi
Sareum Holdings Plc
Savoy Pharmaceuticals Inc
Scholar Rock Inc
Scopus BioPharma Inc
Seattle Genetics Inc
Serum Institute of India Ltd
Sesen Bio Inc
SetLance srl
Seven and Eight Biopharmaceuticals Corp
Shionogi & Co Ltd
Sillajen Biotherapeutics
Sitka Biopharma Inc
Sotio AS
Spectrum Pharmaceuticals Inc
Spring Bank Pharmaceuticals Inc
Stcube Inc
Syndax Pharmaceuticals Inc
T-Cure Bioscience Inc
Targovax ASA
Tarus Therapeutics Inc
Tempest Therapeutics Inc
Tessa Therapeutics Pte Ltd
Theralase Technologies Inc
Tmunity Therapeutics Inc
Tolero Pharmaceuticals Inc
Tollys SAS
Toray Industries Inc
Transgene SA
Treos Bio Ltd
UbiVac LLC

UroGen Pharma Ltd
VasGene Therapeutics Inc
Vault Pharma Inc
Vaxiion Therapeutics Inc
Viralytics Pty Ltd
VivImmune Inc
Vyriad Inc
Xbrane Biopharma AB
Xiangxue Life Sciences
Zhejiang Teruisi Pharmaceutical Inc
Zhejiang Yangshengtang Biotech Co Ltd
Zymeworks Inc

I would like to order

Product name: Bladder Cancer - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/B21AD9F58C2EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B21AD9F58C2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970